Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Johnson and Johnson
Healthtrust
Merck
Julphar

Generated: June 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209963

« Back to Dashboard

NDA 209963 describes GOPRELTO, which is a drug marketed by Genus Lifesciences and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the GOPRELTO profile page.

The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cocaine hydrochloride profile page.
Summary for 209963
Tradename:GOPRELTO
Applicant:Genus Lifesciences
Ingredient:cocaine hydrochloride
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 209963
Generic Entry Date for 209963*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
SOLUTION;NASAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for 209963
Suppliers and Packaging for NDA: 209963
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963 NDA Genus Lifesciences Inc. 64950-359 64950-359-04 1 BOTTLE, GLASS in 1 CARTON (64950-359-04) > 4 mL in 1 BOTTLE, GLASS
GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963 NDA AUTHORIZED GENERIC Genus Lifesciences Inc. 64950-362 64950-362-04 1 BOTTLE, GLASS in 1 CARTON (64950-362-04) > 4 mL in 1 BOTTLE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;NASALStrength4%
Approval Date:Dec 14, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 14, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Feb 7, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
Patent:➤ Sign UpPatent Expiration:Feb 7, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Teva
Federal Trade Commission
Johnson and Johnson
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.